ST PHARM
ST PHARM Co., Ltd. (“ST PHARM”) is a Contract Development and Manufacturing Organization (CDMO) providing phase-appropriate development and manufacturing services for APIs, intermediates, and target compounds to global pharmaceutical and biotech clients. It operates two cGMP-certified facilities in Sihwa and Banwol, with a strong track record of regulatory audits by agencies such as the US FDA, EMA, PMDA, TGA, ANVISA, MFDS, and WHO.
With decades of expertise, ST PHARM has been a trusted supplier of small molecule new chemical entity (NCE) target compounds for antiviral drugs, including HIV, HBV, and HCV. It is particularly recognized for its leadership in nucleoside/tide chemistry-based pharmaceuticals.
Leveraging this expertise, ST PHARM entered the oligonucleotide CDMO business in the early 2000s. Now among the top three global CDMOs in this field, it successfully launched commercial oligonucleotide therapeutics in 2022, with multiple Pre-Approval Inspections (PAIs) scheduled for 2024 and 2025.
ST PHARM has also developed proprietary materials such as SmartCap® (a 5'-capping analog) and STLNP® (ionizable lipids for LNP formulations), essential for mRNA therapeutics. These innovations are supporting the commercialization of mRNA-based drugs. Additionally, ST PHARM is expanding its capabilities in circular RNA (circRNA) manufacturing to drive next-generation RNA therapeutics.
As a leading CDMO in gene therapy, ST PHARM continues to enhance its technologies to ensure the success of clients' mRNA and RNA-based programs worldwide.